Haloperidol

Limits on what this shows

• Null/negative findings: In the 2023 human HepG2 cell-line study, haloperidol produced no significant effect on any mitochondrial parameter in intact cells at concentrations up to 100 micromolar, roughly a thousand-fold above typical clinical plasma exposure; the inhibitory effect emerged only in isolated mitochondria, a more sensitive but less physiologically intact preparation.
• At-risk subgroups: Not established in humans; the mouse in vivo data suggest brain regions relevant to extrapyramidal motor control (striatum, frontal cortex, midbrain) are most affected.

Regulatory status

Not addressed in the FDA label.

Population evidence

Balijepalli, Boyd, and Ravindranath, Neuropharmacology 1999 (PMID 10082817): mouse brain slices in vitro; haloperidol produced time- and concentration-dependent complex I inhibition (43 percent at 100 nM, 58 percent at 1 micromolar), the most potent of the neuroleptics tested (haloperidol greater than chlorpromazine greater than fluphenazine greater than risperidone; clozapine showed no inhibition at 100 micromolar); pretreatment with glutathione and alpha-lipoic acid prevented the effect, and dithiothreitol fully reversed it, confirming thiol oxidation as the mechanism. Balijepalli, Kenchappa, Boyd, and Ravindranath, Neurochem Int 2001 (PMID 11274672): mice given a single dose of haloperidol in vivo showed selective complex I inhibition in frontal cortex, striatum, and midbrain (up to 41 and 26 percent in different regions), abolished by thiol-antioxidant pretreatment, with atypical antipsychotics (clozapine, risperidone) showing more limited regional effects, a pattern the authors tie to the relative extrapyramidal-toxicity liability of each drug (a mechanism clarification, not itself graded, per Hard Rule 2). Rosell-Hidalgo et al., Biomedicines 2023 (PMID 38137493): among 22 psychotropic drugs tested, haloperidol showed no significant effect on mitochondrial parameters in intact human HepG2 cells up to 100 micromolar, but in isolated rat liver mitochondria (high-resolution respirometry) decreased respiration to 85 percent of control at 20 micromolar and 77 percent at 50 micromolar, and dissipated mitochondrial membrane potential to 88 percent and 69 percent respectively. A 1993 human-tissue study (Burkhardt et al., Ann Neurol, title and journal confirmed, PMID 8098932) reporting that neuroleptic medications inhibit complex I of the electron transport chain could not be opened this review; see Sources access note.

Mechanism

Haloperidol oxidizes essential protein thiol groups on complex I (NADH ubiquinone oxidoreductase) to disulfides, inhibiting electron transport chain function; the effect is reversible by thiol-reducing agents in vitro and preventable by thiol-antioxidant pretreatment in vivo, a named and repeatedly confirmed mechanism.

Counter-evidence held on record

Intact human liver cells tolerated haloperidol without measurable mitochondrial disruption at concentrations far above clinical range; effects were seen only in isolated mitochondria (more sensitive, less intact) or in mouse brain tissue at doses/concentrations not directly translatable to routine human oral dosing. This entry shares its underlying source set with ATP production below; see Overlap map, not two independent confirmations. Do not interpret this entry as support for mitochondrial-support supplementation, such as coenzyme Q10, alpha-lipoic acid, or glutathione precursors, in patients on haloperidol; no clinical trial in haloperidol-treated patients has tested this, and the one directly relevant haloperidol-specific antioxidant trial for a related endpoint failed, see Fails verification.

Limits on what this shows

• Null/negative findings: Yao et al. explicitly caution that, despite the observed within-subject difference, haloperidol "may not have direct regulatory effect" on antioxidant defense system enzyme activities, a hedge against overclaiming direct causation from their own data.
• At-risk subgroups: Higher haloperidol dose (protein carbonyl correlation); longer illness duration (glutathione peroxidase); patients developing akathisia (catalase correlation, itself a haloperidol-associated adverse reaction, not a graded finding on its own per Hard Rule 2).

Regulatory status

Not addressed in the FDA label; this is investigational research literature, not a labeled adverse reaction.

Population evidence

Yao et al., J Psychiatr Res 1998 (PMID 9789981): 38 male schizophrenia patients compared drug-free versus haloperidol-treated states within the same subjects. Superoxide dismutase (SOD) activity was significantly higher than matched normal controls during the drug-free period (p=0.009); SOD and glutathione peroxidase (GSH-Px) activities were both higher during the drug-free period than during haloperidol treatment, i.e. lower while on the drug. Boskovic et al., Psychiatry Res 2013 (PMID 23896024): 52 outpatients with schizophrenia on long-acting haloperidol decanoate (4.2 to 50 mg/week), no control group. Higher haloperidol dose correlated positively with increased plasma protein carbonyls (a marker of oxidative protein damage); longer illness duration correlated with lower glutathione peroxidase; decreased catalase activity correlated with greater akathisia severity.

Mechanism

Thiol-oxidation-mediated inhibition of mitochondrial complex I (see Mitochondrial burden entry and Overlap map) is the leading Tier B mechanistic candidate for downstream reactive-oxygen generation and consumption of enzymatic antioxidant capacity in haloperidol-exposed tissue, though neither human study measured complex I directly.

Counter-evidence held on record

Boskovic et al. had no comparison group of unmedicated or healthy subjects, so the dose-protein-carbonyl correlation cannot separate haloperidol's own contribution from illness-driven oxidative stress that exists independent of treatment. Yao et al.'s sample was small (n=38), male-only, and the authors' own interpretation stops short of claiming a direct causal, regulatory effect. Do not interpret this entry as support for general antioxidant or coenzyme Q10 supplementation in patients on haloperidol; no randomized trial in haloperidol-treated patients has tested whether antioxidant supplementation normalizes these markers or changes any clinical outcome, and the one direct haloperidol-specific antioxidant trial for a related endpoint (coenzyme Q10 against dyskinesia) failed, see Fails verification.

Limits on what this shows

• Null/negative findings: No significant change in serum ferritin was found in the rat study despite the liver iron deposition finding. No human study directly measuring serum iron before and after haloperidol initiation (a true depletion design) was located.
• At-risk subgroups: Female sex, in the animal data specifically. In the human risk-marker literature, patients with pre-existing low serum iron or ferritin before or during antipsychotic treatment, for akathisia and NMS risk assessment, not for a haloperidol-induced deficiency.

Regulatory status

Not listed in the FDA label as an adverse reaction or monitoring parameter tied to iron status.

Population evidence

Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats, BMC Pharmacol Toxicol 2021/2022 (PMID 34742342): 60 rats (10 per sex per group), haloperidol 1 mg/kg/day for 12 weeks (postnatal day 85 to 165) versus control and versus clozapine. Female haloperidol-treated rats showed significantly more erythrocytes than controls (p=0.014) but lower hemoglobin (p=0.037) and lower hematocrit (p=0.034); 6 of 10 female haloperidol rats showed ferric iron (Fe3+) deposits in liver tenfold higher than controls (p=0.034), with a negative correlation between transferrin-bound iron and hepcidin (rho=-0.929, p=0.001); no significant change in serum ferritin. Male haloperidol rats instead showed increased mean corpuscular hemoglobin (p=0.001) and lower red cell distribution width (p=0.022), the opposite pattern from females. White and Brown, "Low Serum Iron Levels and Neuroleptic Malignant Syndrome," Am J Psychiatry 1991;148(1):148 (a one-page clinical letter, confirmed via Crossref metadata; full text could not be retrieved this review, see Sources access note): proposes low serum iron as a possible risk marker preceding NMS onset. Schoretsanitis, Nikolakopoulou, Guinart, Correll, and Kane, Eur Neuropsychopharmacol 2020;35:1-11 (PMID 32713729): systematic review and meta-analysis of 10 cross-sectional studies, 395 participants (182 with akathisia, 213 without), pooling first- and second-generation antipsychotics; iron was significantly lower in patients with akathisia (fixed-effect standardized mean difference -0.49, 95 percent CI -0.28 to -0.70, p<0.001), ferritin lower in the fixed-effect model only (SMD -0.32, p=0.007). The review notes haloperidol's akathisia incidence (24.1 percent) in its background prevalence data, but this dossier could not confirm from the accessible abstract that haloperidol-treated patients were specifically among the 10 pooled iron/ferritin studies; treated here as class-level, cohort composition unconfirmed (Hard Rule 6 cohort test caveat).

Mechanism

For the rat findings: a negative correlation between transferrin-bound iron and hepcidin in females suggests altered iron-regulatory signaling accompanying long-term haloperidol exposure, though the exact causal chain is not established. For the NMS and akathisia literature: the proposed direction runs from pre-existing low iron toward increased vulnerability to two haloperidol-associated adverse reactions (dopaminergic dysregulation is more severe when iron-dependent dopamine-synthesis and receptor pathways are already compromised), not from haloperidol toward iron depletion; both source papers for this direction explicitly describe causality as undetermined.

Counter-evidence held on record

The rat sex-dependent findings have not been replicated in an independent cohort or in humans. Both human-literature sources on iron and adverse-reaction risk explicitly state that causality (does low iron predispose to the reaction, or does the reaction or its treatment lower iron) is undetermined; this dossier presents the risk-marker framing as the better-supported reading per Hard Rule 4, not as an established haloperidol depletion effect. This entry shares its primary animal source with Oxygen delivery/utilization below; see Overlap map. Do not supplement iron in a patient on haloperidol without a lab-confirmed low ferritin or iron panel. Iron overload carries its own toxicity risk; any repletion dose should be prescriber-directed and kept under the NIH Office of Dietary Supplements tolerable upper intake level for elemental iron (45 mg/day for adults). This dossier makes no standing dosing recommendation. Checking iron status is reasonable context if a patient develops akathisia or signs suggestive of NMS, but low iron is not itself diagnostic of either, and iron repletion is not an established treatment for either.

Limits on what this shows

• Why no grade: The dual condition for ungraded status is met in substance but with an important caveat: a candidate source that would likely support at least a yellow grade was located (see below) but could not be opened, so this dossier cannot respons­ibly assign a color based on a title alone, consistent with the prohibition on citing a source that was not opened. No circulating claim naming haloperidol and copper together was located to rebut as white.

Channels tried

PubMed search-listing page (multiple phrasings: "haloperidol copper", direct term query) returned 17 results and identified "The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia" (2004, PMID 15466963), which by title directly measures plasma copper in haloperidol- and risperidone-treated patients. The individual PubMed article page for this PMID returned only a reCAPTCHA verification screen, not the abstract, on repeated attempts. Semantic Scholar Graph API lookup by PMID returned an HTTP 429 rate-limit response on two attempts spaced several minutes apart. Europe PMC REST API lookup by external ID was blocked by session-level proxy rejection (429) on two attempts. A separate Frontiers in Psychiatry 2025 article on serum ceruloplasmin and executive function in schizophrenia (Kuang, Wei, Qin, PMID not captured) was successfully retrieved but does not mention haloperidol or any specific antipsychotic and is illness-associated rather than drug-specific, so it does not support even a yellow grade under Hard Rule 6.

Outcome

A likely Tier A, haloperidol-specific candidate source exists (PMID 15466963) but this review could not confirm its direction, magnitude, or statistical significance for haloperidol's plasma copper findings specifically, after genuine attempts across three independent bibliographic channels beyond the original PubMed listing search. The only fully retrieved copper literature for this review (Kuang et al. 2025) is illness-associated, not haloperidol-specific, and under Hard Rule 6 does not itself support a graded claim about haloperidol's own pharmacological effect on copper.

Genuine gap vs tooling limited

Assessed as substantially tooling-limited rather than a confirmed genuine gap: a specific, plausibly relevant, drug-specific source was identified by title and PMID but could not be read. A future revision should prioritize re-attempting PMID 15466963 (title: "The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia," 2004) before treating this gap as fully closed; if its findings show a real haloperidol-specific copper effect, this entry should be upgraded accordingly.

Limits on what this shows

• Null/negative findings: No human cohort study measuring gut microbiome composition specifically in haloperidol-treated patients was located in the channels accessible during this review.
• At-risk subgroups: Not established in humans; theoretical only.

Regulatory status

Not addressed in the FDA label.

Population evidence

Rout, Kar, Dubey, Kispotta, Sarangi, and Prusty, "Neuroprotective effect of Bacillus subtilis in haloperidol induced rat model, targeting the microbiota-gut-brain axis," J Mol Histol 2025;56(1):18: a haloperidol-induced rat model of Parkinsonian-type motor and gut-brain-axis change; the probiotic-intervention arm "reduced the gut microbial dysbiosis, which in turn raised the concentration of good bacteria, i.e. Bifidobacterium, and reduced the concentration of E. coli," implying that haloperidol exposure alone shifted the gut microbiota toward lower Bifidobacterium and higher E. coli -type organisms; exact compositional and diversity metrics for the haloperidol-only arm were not available from the sections of the article retrieved during this review.

Mechanism

Not detailed in the retrieved sections; the broader antipsychotic-microbiome literature (established mainly for second-generation drugs such as olanzapine, clozapine, and risperidone, not stratified to haloperidol) proposes drug-driven shifts in gut microbial composition affecting host metabolic and possibly central nervous system signaling via the gut-brain axis, offered here as class-level context only, not as confirmed for haloperidol.

Counter-evidence held on record

The single located haloperidol-specific source is an animal model with a probiotic-intervention design; it was not designed as a controlled dysbiosis-characterization study, and precise compositional data for the haloperidol-only arm could not be confirmed from the material retrieved this review. No probiotic strain or dose has clinical trial support in haloperidol-treated patients. Do not substitute probiotic supplementation for standard psychiatric and metabolic monitoring.

Limits on what this shows

• Null/negative findings: No effect on ATP-relevant mitochondrial parameters was found in intact human liver cells at concentrations up to 100 micromolar, and no in vivo or clinical human energy-metabolism study (fatigue, exercise capacity, lactate) in haloperidol-treated patients was located.
• At-risk subgroups: Not established; findings come from a toxicological, supratherapeutic exposure range in isolated organelles, not chronic therapeutic human dosing.

Regulatory status

Not addressed in the FDA label.

Population evidence

Rosell-Hidalgo et al., Biomedicines 2023 (PMID 38137493): in isolated rat liver mitochondria, haloperidol decreased oxygen consumption rate (a proxy for oxidative-phosphorylation-linked ATP synthesis capacity) to 85 percent of control at 20 micromolar and 77 percent at 50 micromolar, with membrane potential falling in parallel; no significant ATP-relevant effect was seen in intact human HepG2 cells at up to 100 micromolar. Balijepalli et al. 1999 and 2001 (see Mitochondrial burden entry, same sources) demonstrate the upstream complex I inhibition that would be expected to limit ATP synthesis if replicated at physiologically relevant concentrations in vivo.

Mechanism

Complex I is the entry point of the mitochondrial electron transport chain; thiol-oxidation-mediated inhibition of complex I (see Mitochondrial burden) would be expected to reduce downstream ATP synthesis, and the isolated-mitochondria respirometry data are consistent with this, though this entry shares its primary source with Mitochondrial burden above and is not independent confirmation; see Overlap map.

Counter-evidence held on record

The concentrations required to demonstrate an ATP-relevant effect (20 to 50 micromolar in isolated mitochondria) are roughly a thousand-fold above typical steady-state clinical plasma haloperidol concentrations, and no effect was seen at all in an intact human cell system at up to 100 micromolar. Does not support ATP-support supplementation, such as coenzyme Q10 or creatine, in patients on standard therapeutic haloperidol dosing.

Limits on what this shows

• Null/negative findings: Male rats in the same study showed no hemoglobin or hematocrit reduction, and in fact showed increased mean corpuscular hemoglobin, the opposite direction from females. No cohort or case-control study measuring hemoglobin or hematocrit in haloperidol-treated human patients broadly (outside this single case report) was located.
• At-risk subgroups: Not established in humans beyond the single case report; female sex in the animal data. Patients with pre-existing low WBC or prior drug-induced leukopenia are labeled as at elevated risk for the (separate, white-cell) hematologic adverse reactions.

Regulatory status

The FDA label does not list anemia or hemoglobin/hematocrit change among labeled adverse reactions. Leukopenia, neutropenia, and agranulocytosis (fatal cases reported) are listed as post-marketing hematologic adverse reactions, primarily white-cell, not red-cell or oxygen-carrying, phenomena. QT-interval prolongation, Torsades de Pointes, and sudden death are labeled cardiovascular warnings, worsened by hypokalemia, hypomagnesemia, and higher doses; this is the drug's own intended-adjacent cardiac pharmacology and is excluded from nutrient-style grading per Hard Rule 2.

Population evidence

Jagtiani, Veigne, Lescouflair, and Balan, "Haloperidol Decanoate Induced Pancytopenia: A Case Report," Am J Geriatr Psychiatry 2020;28(4):S115-S116: an 85-year-old woman on haloperidol decanoate 50 mg monthly IM developed WBC nadir 1860/mm3 (from baseline 3000/mm3), hemoglobin nadir 10.1 g/dL (from baseline 10.9 g/dL), and platelet nadir 140,000/mm3; all counts normalized over roughly 3 months after discontinuation (hemoglobin rose to 11.2 g/dL). The primary finding is leukopenia/pancytopenia; the hemoglobin change was modest. Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats, BMC Pharmacol Toxicol 2021/2022 (PMID 34742342, same source as the Iron entry): female haloperidol-treated rats showed significantly lower hemoglobin (p=0.037) and lower hematocrit (p=0.034) than controls, despite a higher erythrocyte count; males showed no comparable reduction. Desai et al., Pharmacogenomics J 2003 (PMID 12746733): human RCT crossover in healthy volunteers, single 10 mg oral haloperidol dose produced statistically significant QTc prolongation versus placebo (mean 421.6 plus or minus 20.1 ms versus 408.4 plus or minus 18.5 ms, p=0.0053), a direct pharmacologic cardiac effect, not a nutrient finding, cited here only to document the mechanism excluded from grading.

Mechanism

For the case report and rat hematologic findings: not established as a single pathway; idiosyncratic bone-marrow suppression is the leading explanation for the case-report pancytopenia, and altered iron-hepcidin signaling (see Iron entry) is the leading candidate for the rat anemia finding. For QT prolongation: direct cardiac ion-channel effects of haloperidol, worsened by hypokalemia and hypomagnesemia, a labeled, dose-related, drug-intrinsic mechanism, not a nutrient-deficiency mechanism.

Counter-evidence held on record

The weight of the haloperidol hematologic case-report literature concerns white-cell suppression (leukopenia, neutropenia, agranulocytosis), not anemia; the pancytopenia case report's hemoglobin change was modest relative to its white-cell change. The rat anemia finding did not replicate in males. This entry shares its primary animal source with Iron above; see Overlap map, not counted as independent confirmation. A single case report and a sex-limited animal finding cannot establish causation. QT-interval prolongation risk should be managed through baseline and periodic ECG and electrolyte monitoring (see Monitoring panel), never through nutrient supplementation; hypokalemia and hypomagnesemia should be corrected as part of standard cardiac risk management, not as a response to a haloperidol-induced nutrient deficiency, since none is established.